FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Videos|November 25, 2020
The Vulnerability and Resilience of Refugees During the Pandemic
Assisting and empowering refugees is important now more than ever.
Advertisement
Andrea Mendiola, MD, and Lilanthi Balasuriya, MD, MMS, discuss and present ideas from their article,
Dr Mendiola is a Fellow, Connecticut Mental Health Center Hispanic Clinic, and Dr Balasuriya is a Fourth Year Resident, Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
The New, Impending Adult ADHD Guidelines
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
5